Chondroitins 4 and 6 Sulfate in Osteoarthritis of the Knee - A Randomized, Controlled Trial
Beat A. Michel,1 Gerold Stucki,2 Diana Frey,1 Florent De Vathaire,3 Eric Vignon,4
Pius Bruehlmann,1 and Daniel Uebelhart1
1 Beat A. Michel, MD, Diana Frey, MD, Pius Bruehlmann,
MD, Daniel Uebelhart, MD: University Hospital Zurich, Zurich, Switzerland; 2 Gerold Stucki, MD, MS: University of Munich, Munich,
Germany; 3 Florent De Vathaire, MD: Institut Gustave-Roussy, Villejuif,
France; 4 Eric Vignon, MD: Centre Hospitalier Lyon Sud, Pierre-
Objective. To determine whether chondroitin sulfate
(CS) is effective in inhibiting cartilage loss in knee
Methods. In this randomized, double-blind,
placebo-controlled trial, 300 patients with knee OA were recruited from an outpatient clinic, from private practices,
and through advertisements. Study patients were
randomly assigned to receive either 800 mg CS or
placebo once daily for 2 years. The primary outcome was
joint space loss over 2 years as assessed by a posteroanterior
radiograph of the knee in flexion; secondary
outcomes included pain and function.
Results. Of 341 patients screened, 300 entered the
study and were included in the intent-to-treat analysis.
The 150 patients receiving placebo had progressive joint space narrowing, with a mean SD joint space loss of 0.14 ± 0.61 mm after 2 years (P = 0.001 compared with baseline). In contrast, there was no change in mean joint space width for the 150 patients receiving CS (0.00 ± 0.53 mm; P not significant compared with baseline). Similar results were found for minimum joint space narrowing. The differences in loss of joint space between the two groups were significant for mean joint space width (0.14 ± 0.57 mm; P = 0.04) and for minimum joint space width (0.12 ± 0.52 mm; P = 0.05). CS was well tolerated, with no significant differences in rates of adverse events between the two groups.
Conclusion: While there was no significant symptomatic
effect in this study, long-term treatment with CS
may retard radiographic progression in patients with
OA of the knee. However, the clinical relevance of the
observed structural results has to be further evaluated,
and further studies are needed to confirm the structural
effects of CS.
Source: Arthritis & Rheumatism Vol.52, No. 3, March 2005, pp. 779-786.